Averitas Pharma

Averitas Pharma, a leader in the US for holistic pain management, was formed in 2018 as the US commercial subsidiary of The Grünenthal Group. The first innovation from Averitas Pharma in the US is QUTENZA® (capsaicin) 8% topical system, which is a result of acquisitions in 2016 and 2018. These acquisitions give Grünenthal global commercial rights to QUTENZA and provide Averitas with its first FDA-approved product for distribution. Discover The QUTENZA Difference by meeting with our team.